ArticleThe international journal of cardiovascular imaging2026
Left atrial myopathy predicts cardiovascular outcome in hypertension and diabetes.
Article in The international journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arterial hypertension (AH) and type 2 diabetes mellitus (T2DM) predispose to left atrial (LA) dysfunction and atrial myopathy. We assessed the ability of peak atrial longitudinal strain (PALS) to predict major adverse cardiovascular events (MACEs) in AH and/or T2DM. We retrospectively enrolled patients > 40 years, in sinus rhythm, with AH and/or T2DM. Standard and advanced echocardiographic indices were collected; patients with previous MACEs, cardiac surgery, pacemakers, or moderate-to-severe valvular disease were excluded. The composite endpoint included atrial fibrillation, heart failure hospitalization, transient ischemic attack, stroke, myocardial infarction/coronary revascularization, and cardiovascular/all-cause mortality. Study population: 292 patients (63.0 ± 9.6 years, 50% female; 202 hypertensives, 167 diabetics, 77 with both). All patients had preserved left ventricular ejection fraction (58.2 ± 4.9), mild-to-moderate LA dilatation (52.9 ± 24.9 ml) and dysfunction (PALS 29.7 ± 11.1%). During 11.2 ± 1.3 years follow-up, 110 patients experienced ≥ 1 event; they had similar EF but were older (65.8 ± 9.0 vs. 61.3 ± 9.6 years, p < 0.001) and with poorer PALS (21.6 ± 7.7 vs. 34.6 ± 9.9%, p < 0.001) than those without events. On multivariate analysis, sex, age, systolic pulmonary artery pressure, and PALS were independently associated with outcomes, with PALS showing the strongest association (PALS < 22.5% HR 18.99; 22.5-30% HR 7.68; p < 0.001). Sex sub-analysis confirmed PALS powerful prognostic performance in women. PALS < 22.5% was related to 1-, 5-, and 10-year survival of 82.4%, 49.8% and 25.3%; for PALS > 30%: 100%, 98.5% and 92.5%. PALS, a surrogate marker of LA myopathy, is a strong prognosticator in patients with long standing T2DM and AH, thus should be routinely used in primary prevention.
Indexed as
Identifiers
42671700What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.